Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — Q4 2021 Earnings Presentation

38 slides from Neurocrine Biosciences's earnings presentation, Feb 11, 2022

  1. Slide 1: Q4 2021 / Year-End Corporate Presentation

    Advancing Life-Changing Discoveries in Neuroscience Q4 2021 / Year-End Corporate Presentation February 11, 2022 Nasdaq: NBIX

  2. Slide 2: Safe Harbor Statement and Non-GAAP Financial Measures

    Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our

  3. Slide 3: Well Positioned for Sustained & Long-term Growth

    Well Positioned for Sustained & Long-term Growth ~450,000 * Exceeded Annual Sales undiagnosed and untreated patients of ~$1B in 2021 with TD in the U.S. (Less than 5 Years Since Launch) Significant Opportunity for Growth 12 Programs Currently in R&D Focus Robust Mid-to-Late-Stage Studies • Neurology

  4. Slide 4: Q4 & FY 2021 Highlights and Future Key Milestones & Activities

    Q4 & FY 2021 Highlights and Future Key Milestones & Activities Q4 2021 & FY Highlights Future Key Milestones & Activities ▪ INGREZZA® (valbenazine) Net Product Sales of ~$1.1 Billion ▪ Continued INGREZZA Commercial Execution with 200,000 TRx in 2021 − Complete Salesforce Expansion by End of Q1 2022

  5. Slide 5: Strong Pipeline Momentum

    Strong Pipeline Momentum Phase 1 Phase 2 Phase 3 Partner Upcoming Milestones Neurology valbenazine* Tardive Dyskinesia (MTPC) Approval in Japan Expected in 2022 Supplemental New Drug Application (sNDA) valbenazine* Chorea in Huntington Disease Filing in 2H 2022 valbenazine* Dyskinetic Cerebral Palsy

  6. Slide 6: Pipeline Features Novel Mechanisms to Treat Intractable Diseases

    Pipeline Features Novel Mechanisms to Treat Intractable Diseases Focused on Neurology, Neuroendocrinology, and Neuropsychiatry Neurology Neuroendocrinology Epileptic SCN8A Encephalopathy Focal Onset Developmental Tardive Essential with Continuous Seizures (FOS) and Epileptic Endometriosis Dyskinesia

  7. Slide 7: Significant Clinical Progress Expected Over the Next Two Years

    Significant Clinical Progress Expected Over the Next Two Years Significant Milestones This Year 2023 Clinical Activities & Milestones Valbenazine in Chorea in Huntington Disease Crinecerfont for CAH in Adults sNDA Filing Registrational Top-line Data NBI-827104 in EE-CSWS Crinecerfont for CAH in Chil

  8. Slide 8: Significant Milestones This Year

    Significant Milestones This Year Valbenazine* NBI-827104** NBI-827104** Chorea in HD Essential Tremor EE-CSWS sNDA filing in 2H 2022 Phase 2 data in Mid-2022 Phase 2 data in 2H 2022 T-type calcium channel blocker T-type calcium channel blocker VMAT2 inhibitor (Cav 3.1, Cav 3.2, Cav 3.3) (Cav 3.1, Ca

  9. Slide 9: 2021 Annual Financial Summary

    2021 Annual Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item 2021 2020 Highlights / Comments Revenue $1,133 $1,046 - Product Sales, Net 1,090 994 INGREZZA Sales of ~$1.1 Billion - Collaboration Revenue 43 52 YoY Increase Driven by Expanded / Advancing Non-GAAP R&D Expense 280 24

  10. Slide 10: Q4 2021 Financial Summary

    Q4 2021 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q4 2021 Q4 2020 Highlights / Comments Revenue $312 $248 INGREZZA YoY Sales and TRx Grew 25% and 32%, - Product Sales, Net 304 241 Respectively - Collaboration Revenue 8 7 Increase to Support Expanded / Advancing Portfolio,

  11. Slide 11: 2022 INGREZZA Sales and Operating Expense Guidance

    2022 INGREZZA Sales and Operating Expense Guidance Item ($ Millions) 2021 Actuals 2022 Guidance Range INGREZZA Net Product Sales1 $1,082 $1,250 - $1,350 GAAP R&D Expense2 $328 $410 - $430 Non-GAAP R&D Expense3 $280 $350 - $370 GAAP SG&A Expense4 $583 $690 - $720 Non-GAAP SG&A Expense3 $498 $580 - $6

  12. Slide 12: Our Medicines, Our Patients

    Our Medicines, Our Patients Q4 2021 and Full-Year Earnings Presentation

  13. Slide 13: INGREZZA Quarterly Net Sales Performance

    INGREZZA Quarterly Net Sales Performance ($MM) $320 3rd Sequential Quarter of Growth in Covid-Era $301 $300 $287 $280 $268 $265 $260 $254 $240 $240 $231 $230 $220 $200 Q1 '20 Q2 '20 Q3 '20 Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21 13

  14. Slide 14: Substantial Impact on TD Patients and Caregivers

    Substantial Impact on TD Patients and Caregivers Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications Uncontrollable, abnormal and repetitive movements >50% of patients experience meaningful emotional, social and psychological impact* Job Performance Low Self-Worth

  15. Slide 15: Nascent TD Market Presents Significant Opportunity

    Nascent TD Market Presents Significant Opportunity ~25% E S T I M AT E D T O A F F E C T ~600,000 people in the U.S. patients with TD diagnosed Increasing Antipsychotic Prescriptions (U.S.) ~75 % 19.0 3% Compound Annual TRx (Millions) Growth Rate from 2017 - 2021 18.0 17.0 market is not yet diagnose

  16. Slide 16: Driving Long-Term Growth for INGREZZA

    Driving Long-Term Growth for INGREZZA Salesforce and distribution expansion INGREZZA and ONGENTYS offering greater access to neurology practices Investing in telemedicine capabilities Recommends patients with TD associated with antipsychotic therapy be treated with a VMAT2 inhibitor Patient outreach

  17. Slide 17: Filing sNDA for Valbenazine for Chorea in Huntington Disease in 2H 2022

    Filing Supplemental New Drug Application for Valbenazine for the Treatment of Chorea in Huntington Disease in 2H 2022 Valbenazine* Simple once-a-day treatment targeted for symptom control of chorea movements Promising safety profile supported by extensive safety data in tardive dyskinesia In randomi

  18. Slide 18: Valbenazine: Registrational Programs in ATS and DCP

    Valbenazine*: Registrational Programs in ATS and DCP with Top-Line Data Expected for Both Programs in 2023 Adjunctive Treatment of Schizophrenia (ATS) Dyskinetic Cerebral Palsy (DCP) Schizophrenia is one of the leading causes A form of cerebral palsy (CP) that affects of disability worldwide, affect

  19. Slide 19: ONGENTYS Is the 1st and Only FDA-Approved Once-Daily COMT Inhibitor

    ONGENTYS Is the 1st and Only FDA-Approved Once-Daily COMT Inhibitor for Parkinson’s Disease Provides Significant Reduction of Daily “Off” Time; Increase in Good “On” Time • Add-on treatment to levodopa/carbidopa prolongs clinical effects • One capsule, once a day treatment • Helps patients achieve m

  20. Slide 20: Classic Congenital Adrenal Hyperplasia (CAH)

    Classic Congenital Adrenal Hyperplasia (CAH) Rare Genetic Disorder • Enzyme deficiency • Reduced cortisol U.S. Europe levels and excess ~30,000* ~50,000* androgen levels Complex and Highly Treatment Options Variable Stagnant for 60 Years Symptoms • Hormone replacement • Do not address underlying iss

  21. Slide 21: Congenital Adrenal Hyperplasia Disease Mechanism

    Congenital Adrenal Hyperplasia Disease Mechanism Normal Homeostasis CAH Patients 21

  22. Slide 22: Crinecerfont Potentially Meets Challenges of the Standard of Care

    Crinecerfont* Potentially Meets Challenges of the Standard of Care Overtreatment Hypercortisolism Overtreatment Insulin Resistance Undertreatment Hypercortisolism Central Obesity Hyperandrogenism Osteoporosis Potentially Fatal Adrenal Crisis Insulin Resistance Impaired Glucose Tolerance CRINECERFONT

  23. Slide 23: Potential Paradigm Shift in the Treatment of CAH

    Potential Paradigm Shift in the Treatment of CAH Crinecerfont* Phase 3 Global Registrational Study in Adults Ongoing Top-Line Results Phase 3 Pediatric Registrational Study Ongoing Expected in 2023 Potent Orally Active Selective Well-Tolerated *Crinecerfont is investigational and not approved in any

  24. Slide 24: Potential First-in-Class Neuropsychiatry Programs: Takeda Collaborations

    Potential First-in-Class Neuropsychiatry Programs Takeda Collaborations Ongoing Clinical Programs in Phase 2 Studies Clinical Programs in Phase 2 Studies Cognitive Impairment Associated Luvadaxistat* Ongoing Phase 2 Study with Schizophrenia (CIAS) Inadequate Response to Treatment in NBI-1065845 Majo

  25. Slide 25: Luvadaxistat: D-Amino Acid Oxidase (DAAO) Inhibitor

    Luvadaxistat*: D-Amino Acid Oxidase (DAAO) Inhibitor Cognitive Impairment Associated with Luvadaxistat Schizophrenia (CIAS) Affects approximately 80% of the 3.5 Potent first-in-class DAAO inhibitor million people in the U.S. diagnosed • Once daily with schizophrenia • No titration requirement Hypofu

  26. Slide 26: Potential First-in-Class Neuropsychiatry Programs: Idorsia and Xenon

    Potential First-in-Class Neuropsychiatry Programs Collaborations with Idorsia and Xenon Ongoing Clinical Programs in Phase 2 Studies Clinical Programs in Phase 2 Studies Essential Tremor Top-line Data Expected in Mid-2022 NBI-827104* Rare Pediatric Epilepsy: EE-CSWS Top-line Data Expected in 2H 2022

  27. Slide 27: NBI-827104: Selective Cav Blocker

    NBI-827104*: Selective Cav Blocker NBI-827104 Investigational, potent, selective, orally active and brain penetrating T-type calcium channel blocker (Cav 3.1, Cav 3.2, Cav 3.3) with 1x/day dosing Program has potential to address other central nervous system diseases Essential Tremor Program EE-CSWS

  28. Slide 28: NBI-827104: Enrolling Patients in Phase 2 Studies

    NBI-827104*: Enrolling Patients in Phase 2 Studies Essential Tremor Background EE-CSWS Background Essential tremor is one of the most common Rare pediatric epilepsy characterized by onset movement disorders, affecting an estimated seizures between 2 and 12 years of age. 10 million people in the U.S.

  29. Slide 29: NBI-921352: Selective Nav 1.6 Inhibitor

    NBI-921352*: Selective Nav 1.6 Inhibitor NBI-921352 Potent, highly selective Nav1.6 inhibitor to precisely target the sodium channel affected by the genetic mutation of SCN8A Program has potential to address other central nervous system diseases Adult Focal Onset Seizures Program SCN8A-DEE Program P

  30. Slide 30: NBI-921352: Ongoing Phase 2 Studies

    NBI-921352*: Ongoing Phase 2 Studies Adult Focal Onset Seizures Background SCN8A-DEE Background Also referred to as partial-onset seizures, Rare pediatric epilepsy with occurrence of these are the most common form of seizures seizures beginning in the first 18 months of in adults, impacting ~1.8 mil

  31. Slide 31: Novel Muscarinic Receptor Agonists Collaboration with Sosei Heptares

    Novel Muscarinic Receptor Agonists Collaboration with Sosei Heptares Neurocrine Biosciences Initiating Clinical Studies for Muscarinic Portfolio Initiating clinical studies, including: ➢ Phase 2 placebo-controlled study of NBI-1117568*, a selective M4 orthosteric agonist, as a potential treatment fo

  32. Slide 32: Well Positioned for Sustained & Long-term Growth

    Well Positioned for Sustained & Long-term Growth ~450,000 * Exceeded Annual Sales undiagnosed and untreated patients of ~$1B in 2021 with TD in the U.S. (Less than 5 Years Since Launch) Significant Opportunity for Growth 12 Programs Currently in R&D Focus Robust Mid-to-Late-Stage Studies • Neurology

  33. Slide 33: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations neurocrine.com

  34. Slide 34: Condensed Consolidated Statements of (Loss) Income

    NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF (LOSS) INCOME (unaudited) (in millions, except per share data) Revenues: Product sales, net Collaboration revenue Total revenues Operating expenses: Cost of sales Research and development Acquired in-process res

  35. Slide 35: Condensed Consolidated Balance Sheets

    CONDENSED CONSOLIDATED BALANCE SHEETS (in millions) NEUROCRINE BIOSCIENCES, INC. (unaudited) Cash, cash equivalents and debt securities available-for-sale Other current assets Total current assets Deferred tax assets Debt securities available-for-sale Right-of-use assets Equity securities Property a

  36. Slide 36: Reconciliation of GAAP to Non-GAAP Financial Results

    NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (unaudited) Three Months Ended Twelve Months Ended December 31, December 31, (in millions, except per share data) 2021 2020 2021 2020 GAAP net (loss) income $ 3) $8 3479 $ 896 $ 4073 Adjustments:

  37. Slide 37: Reconciliation of GAAP to Non-GAAP Expenses

    NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP EXPENSES (unaudited) Three Months Ended ‘Twelve Months Ended December 31, December 31, (in millions) 2021 2020 2021 2020 GAAP R&D $ 874 $ 66.7 $ 328.1 $ 275.0 Adjustments: Share-based compensation expense 12.2 73 48.4 33.7 Non-GAAP R&D

  38. Slide 38: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q4 2021 / Year-End Corporate Presentation February 11, 2022 Nasdaq: NBIX

Neurocrine Biosciences — Q4 2021 Earnings Presentation on 6ix